Actualités 17.04.2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
News 06.05.2024 EY reports growth of 53 percent for investments in Switzerland Foreign investments in Europe fell by 4 percent in 2023. However, investments in Switzerland were up by 53 percent. These findings were reported ...
News 17.04.2024 Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug develop...
News 23.10.2023 Valsynthèse, 40 years of innovation in the canton of Valais From dynamite to pharmaceuticals, Valsynthèse, the 'fine chemistry' business unit of the Société Suisse des Explosifs, celebrates four decades of...
News 10.01.2024 The remarkable chemical-pharmaceutical industry in the canton of Valais For decades, the canton of Valais has cultivated a reputation for excellence in the chemical and pharmaceutical industries, combining innovation ...
News 07.06.2023 Genedata expanding its user network The Japanese biopharmaceutical firm Ajinomoto is to use the Genedata solution to accelerate its drug development processes at its site in South K...
Aktuell 07.06.2023 Genedata weitet Netz seiner Nutzer aus Das japanische Biopharma-Unternehmen Ajinomoto setzt die Lösung von Genedata zur Beschleunigung seiner Medikamentenentwicklung künftig auch an se...
News 25.10.2023 Mecaplast Swiss, 50 years of innovation in the canton of Fribourg With a rich history spanning five decades, Mecaplast Swiss has consistently proven itself as a leader in the plastic injection industry, particul...
Actualités 26.10.2022 Cordis va acquérir la medtech vaudoise MedAlliance pour USD 1,1 milliard Dans le cadre d’une transaction totale pouvant atteindre USD 1,135 milliard, MedAlliance a signé un accord de sortie avec Cordis, un leader mondi...
News 26.10.2022 Cordis to acquire Vaud-based medtech MedAlliance for up to USD 1.1 billion In a total transaction of up to USD 1.135 billion, MedAlliance has signed an exit agreement with Cordis, a worldwide leader in interventional car...
News 13.09.2022 BioLingus develops COVID-19 pills with partners Together with its South Korean partners, CHA Vaccine Institute and PanGen Biotech, BioLingus from the canton of Nidwalden is working on a tablet ...
Aktuell 13.09.2022 BioLingus entwickelt mit Partnern COVID-19-Pille BioLingus arbeitet mit seinen koreanischen Partnern CHA Vaccine Institute und PanGen Biotech an einer Tablette, die Corona-Impfungen ersetzen kan...
News 23.11.2022 Geneva biopharma ObsEva sells its Ebopiprant license for up to USD 113 million Women's and reproductive health specialist ObsEva has announced the sale of its license for ebopiprant to California-based biotech company Xoma f...
Actualités 27.10.2021 ONWARD Medical entre en bourse et lève CHF 93 millions La spin-off de l'EPFL, ONWARD Medical, est entrée en bourse sur Euronext Bruxelles avec une cotation secondaire sur Euronext Amsterdam, portant l...
Actualités 12.10.2021 Le pionnier des neurothérapies MindMaze lève USD 125 millions MindMaze, pionnier mondial sur le marché de la neurothérapie numérique, a levé USD 125 millions auprès d'AlbaCore Capital Group. Cela porte la va...
News 27.10.2021 ONWARD Medical goes public and raises CHF 93 million EPFL spin-off ONWARD Medical went public on Euronext Brussels with a secondary listing on Euronext Amsterdam, bringing the value of the company t...
News 12.10.2021 Neurotherapeutics pioneer MindMaze secures USD 125 million MindMaze, a global pioneer in the digital neurotherapeutics market, raised USD 125 million from AlbaCore Capital Group. This brings the Vaud-base...
Actualités 08.03.2021 Debiopharm signe un contrat de plus de EUR 900 millions avec Merck Debiopharm a accordé une licence mondiale exclusive au géant pharmaceutique Merck pour le développement et la commercialisation de son médicament...